Close Menu

Editas

Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.

 

The court upheld a judgement of no interference-in-fact from the Patent Trial and Appeal Board, leaving the Broad in control of key CRISPR IP.

In exchange, Editas has the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.

The company — which was cofounded by David Liu, Feng Zhang, and Keith Joung — has licensed base editing technology from Harvard and the Broad Institute.

Ready to Go, But?

Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.

On the Verge

The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.

The wide-ranging discussion with witnesses from Stanford, Johns Hopkins, and Editas Medicine touched on recent advances in research and questions of safety.

In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.

The company intends to use part of the proceeds of the offering to advance programs including one in Leber congenital amaurosis 10.

The firm plans to sell 4 million shares of common stock to support preclinical studies and clinical trials of CRISPR-based human therapies, among other uses.

Pages

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.